Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response.

ABSTRACT: Given the high costs of conducting a drug-response trial, researchers are now aiming to use retrospective analyses to conduct genome-wide association studies (GWAS) to identify underlying genetic contributions to drug-response variation. To prevent confounding results from a GWAS to investigate drug response, it is necessary to account for concomitant medications, defined as any medication taken concurrently with the primary medication being investigated. We use data from the Action to Control Cardiovascular Disease (ACCORD) trial in order to implement a novel scoring procedure for incorporating concomitant medication information into a linear regression model in preparation for GWAS. In order to accomplish this, two primary medications were selected: thiazolidinediones and metformin becau

SUBMITTER: Graham HT 

PROVIDER: S-EPMC5013254 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature